Dr. Ryan C. Leibrandt, MD

Dr. Leibrandt practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Leibrandt's NPI, 1801327044, was assigned on March 21, 2017. Dr. Leibrandt graduated from Medical College of Georgia School of Medicine in 2017. Dr. Leibrandt holds California license A172836.

Dr. Leibrandt's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Leibrandt's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Leibrandt is also affiliated with Enloe Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Leibrandt to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leibrandt practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Leibrandt's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Leibrandt is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Leibrandt's licenses on file in 2 states: California and New York.

CMS data shows 326 Medicare services from Dr. Leibrandt across 4 procedure codes in 2024, for 83 Medicare patients. Medicare paid $18,424 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 83 Medicare patients who saw Dr. Leibrandt in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leibrandt's median patient age at 69, with 17% women.

In 2024, Dr. Leibrandt wrote 410 Medicare Part D claims for 58 patients. 75% of them were for generic drugs. CMS names the drug for 257 of them, across 10 drugs with 11 or more claims each, at $1,111,003 in total drug cost. In 2023, CMS named 150 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Leibrandt for performance year 2024, reported as part of a group. Dr. Leibrandt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leibrandt as offering telehealth.

Dmand AI links 5 papers to Dr. Leibrandt, published from 2018 to 2022. 2020 was the busiest year, with 2. The most frequent topics are Goals and Oncologists. Dr. Leibrandt has published most often in JCO Oncol Pract. Dr. Leibrandt's most frequent co-authors are Kerin Bess Adelson, MD, Sofya Pintova, MD and Cardinale B. Smith, MD, PhD.

CMS Open Payments shows 1 general payment to Dr. Leibrandt from 1 drug or device company in 2021. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $125.

Dr. Leibrandt graduated from Medical College of Georgia School of Medicine in 2017.

Dr. Leibrandt is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.